Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration - HAL Accéder directement au contenu
Article dans une revue Health Affairs Année : 2012

Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration

Henry.G Grabowski
  • Fonction : Auteur
  • PersonId : 930935
Margaret Kyle
  • Fonction : Auteur
Richard Mortimer
  • Fonction : Auteur
Genia Long
  • Fonction : Auteur
Noam Kirson
  • Fonction : Auteur

Résumé

The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. Generic drug usage and challenges to brand-name drugs' patents have increased markedly, resulting in greatly increased cost savings but also potentially reduced incentives for innovators. Congress should review whether Hatch-Waxman is achieving its intended purpose of balancing incentives for generics and innovation. It also should consider whether the law should be amended so that some of its provisions are brought more in line with recently enacted legislation governing approval of so-called biosimilars, or the corollary for biologics of generic competition for small-molecule drugs
Loading...
Fichier non déposé

Dates et versions

halshs-00738629, version 1 (04-10-2012)

Identifiants

Citer

Henry.G Grabowski, Margaret Kyle, Richard Mortimer, Genia Long, Noam Kirson. Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration. Health Affairs, 2012, 30 (11), pp.2157-2166. ⟨10.1377/hlthaff.2010.0270⟩. ⟨halshs-00738629⟩
89 Consultations
0 Téléchargements
Dernière date de mise à jour le 28/04/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus